Undisclosed DLL3 x B7H3 bispecific ADC
/ GeneQuantum Healthcare
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 18, 2026
Novel DLL3 x B7H3 bispecific ADC demonstrated superior efficacy in preclinical studies
(AACR 2026)
- "In conclusion, the next-generation bispecific ADC holds great potential to overcome SCLC heterogeneity and improve outcomes for treatment-resistant patients."
ADC • Bispecific • IO biomarker • Preclinical • Endocrine Cancer • Lung Cancer • Neuroendocrine Carcinoma • Oncology • Small Cell Lung Cancer • Solid Tumor • ASCL1 • CD276 • DLL3 • NEUROD1 • POU2F3
1 to 1
Of
1
Go to page
1